German Merck to Build a New US Life Science Hub
14th February 2019
German pharmaceuticals and chemicals group Merck has announced plans to establish a new innovation hub in Billerica, Massachusetts, which will focus oncology, immuno-oncology and immunology.
The state-of-the art research facilities will cost around $70 million and are scheduled to be completed in 2021 will encompass a new laboratory and collaborative working space that can accommodate around 400 new and current scientific employees.
Specifically, the new building will offer wet labs, office space and a cafeteria for the campus. Consistent with previous projects, Merck said the building will be constructed to the highest environmental and employee wellness standards by seeking LEED and WELL building standard certifications.
With this latest project, the German group said it will have invested more than $150 million in infrastructure to advance biopharmaceutical R&D in the state of Massachusetts in recent years, adding more than 150 new jobs to its growing Billerica hub established in 2011.
The town of Billerica played a “critical role in bringing this latest building expansion project to fruition,“ Merck said in a statement, without providing details on any local financial investment incentives.
Luciano Rossetti, global head of R&D for Merck’s biopharma business, said the group’s healthcare business continues to strengthen its innovation footprint in the US as well as at its global R&D headquarters in Darmstadt. "Our talented and passionate R&D teams based in Billerica have been highly engaged in advancing a number of pipeline compounds,” Rossetti said.
Travis McCready, president and CEO of Merck’s Massachusetts Life Sciences Center, added the continued investment in the New England state is “a testament to the state’s global leadership in life sciences." He added: “In working collaboratively with the town of Billerica, the company’s campus expansion over the past decade has not only helped attract and retain top talent in the area, but more importantly, contributed to improving the lives of people with serious medical needs.”
Merck’s US presence is comprised of three businesses – Healthcare, Life Science and Performance Materials – with nearly 10,000 employees working in R&D, manufacturing and corporate roles across almost 60 sites country-wide. Within the state of Massachusetts, more than 2,800 professionals work across 10 locations.
For more information visit www.chemanager-online.com/en/